LYNPARZA® (olaparib) and IMFINZI® (durvalumab) combination reduced risk of disease progression or death by 37% vs. chemotherapy and bevacizumab in patients with advanced ovarian cancer without tumor BRCA mutations in the DUO-O Phase III trial

Positive results from a planned interim analysis of the DUO-O Phase III trial showed that treatment with a combination of LYNPARZA® , IMFINZI® , chemotherapy and bevacizumab demonstrated a... | June 3, 2023

Related Keywords

Paris ,France General ,France ,Cambridge ,Cambridgeshire ,United Kingdom ,United States ,China ,Japan ,Chicago ,Illinois ,Canada ,American ,Susan Galbraith ,National Cancer Institute ,European Society Of Medical Oncology Congress ,World Cancer Research Fund International ,Merck Co Inc ,Astrazeneca ,American Society Of Clinical Oncology ,Intj Womens Health ,Clinical Oncology ,Annual Meeting ,Executive Vice President ,Acute Myeloid Leukemia ,Fetal Toxicity ,First Line Maintenance ,Advanced Ovarian ,First Line Maintenance Advanced Ovarian Cancer ,Maintenance Recurrent Ovarian ,Adjuvant Treatment ,High Risk Early Breast ,Negative Metastatic Breast ,Metastatic Pancreatic ,Metastatic Castration Resistant Prostate ,Metastatic Castration Resistant Prostate Cancer ,Positive Advanced Ovarian Cancer ,Line Maintenance ,Prescribing Information ,Fatal Immune Mediated Adverse ,Mediated Nephritis ,Renal Dysfunction ,Stevens Johnson Syndrome ,Tumor Drivers ,Antibody Drug Conjugates ,Cell Therapies ,Rare Diseases ,Intj Womens ,Cancer Research Fund ,Ovarian Cancer ,Accessed May ,Ovarian Cancer Charter Data ,Cancer Stat Facts ,Overall Survival ,Results From ,Evaluating Maintenance Olaparib ,Plus Bevacizumab ,Newly Diagnosed Advanced Ovarian Cancer ,European Society ,Medical Oncology ,Newly Diagnosed Advanced Ovarian ,For Ovarian ,Astrazeneca Plc Stock Exchange ,News ,Information ,Press Release ,Positive ,Results ,Rom ,Planned ,Interim ,Analysis ,F ,The ,Hase ,Wii ,Trial ,Howed ,Hat ,Treatment ,Ith ,Combination ,Chemotherapy ,End ,Evacizumab ,Emonstrated Azn Gb0009895292 ,